Colaspase (Leunase): Discontinuation

Discontinuation Active

Patients who would have been treated with colaspase (Leunase) can now access pegaspargase. The Special Authority criteria for pegaspargase changed on 1 December 2020.

Sanofi are discontinuing production of colaspase globally. Colaspase was delisted from the Pharmaceutical Schedule on 1 December 2020.

Colaspase was only available in hospitals. This discontinuation affects fewer than 10 patients.

Key dates for prescribers and pharmacists:

1 December 2020 | Colaspase delisted from the Pharmaceutical Schedule

1 December 2020 | Funding criteria for pegaspargase widened 

Information for prescribers

The Cancer Treatments Subcommittee of PTAC (CaTSoP) advised PHARMAC that pegaspargase is an acceptable alternative treatment for patients who would have been treated with colaspase.

From 1 December 2020, PHARMAC widened access to pegaspargase. This widens access to funded pegaspargase for patients with acute lymphoblastic leukaemia and some aggressive lymphomas. 

Find the Special Authority form for pegaspargase(external link)

Pegaspargase on the NZ Formulary(external link)

Information for pharmacists

Colaspase (Leunase) was delisted from 1 December 2020.

Who to contact 

Contact us if you have any questions about funding criteria